{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:15:24Z","timestamp":1788156924087,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tofacitinib is a pan\u2010janus kinase inhibitor (JAK) which has been tested off\u2010label in alopecia areata (AA) with promising results. However, evidence of tofacitinib in real\u2010life setting is still poor. We evaluated long\u2010term efficacy and safety of tofacitinib for refractory AA. This is a prospective, open\u2010label, observational, single\u2010center cohort study conducted between January 2018 and December 2020. Primary end\u2010point was the percent change in Severity of Alopecia Tool (SALT) at the basal visit and at the most recent follow\u2010up visit. Three categories of treatment response were analyzed. Data on 47 participants of Arab\u2010Asian heritage were analyzed. A complete and partial regrowth was observed in 18 patients (41.86%) and 11 patients (25.58%), respectively. In 12 patients (27.9%), no response was obtained. Most of the non\u2010responders belonged to the alopecia universalis group (66.67%). No statistical differences were observed in rates of regrowth between pediatric and adult individuals (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.52), nor between women and men. Significant differences in the average duration of tofacitinib treatment were obtained among the three categories of regrowth (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.003), notably duration of AA did not impact the clinical regrowth (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.62). To the best of our knowledge, this is the first prospective, observational, long\u2010term study using tofacitinib in refractory AA. Rates of regrowth and side effects are analogous to previous works. Length of tofacinitib therapy should last for 12\u2009months before considering any discontinuation or change, since early cessation can lead to treatment failures or incomplete regrowth. Maintenance therapy after complete regrowth has demonstrated to be safe and effective to prevent recurrences of hair loss.\n                  <\/jats:p>","DOI":"10.1111\/dth.15871","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T04:23:00Z","timestamp":1664511780000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real\u2010world experience and long\u2010term evaluation of tofacitinib in refractory alopecia areata: A prospective, open\u2010label, single\u2010center study in Asian Arab population"],"prefix":"10.1155","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7869-0206","authenticated-orcid":false,"given":"Husein","family":"Husein\u2010ElAhmed","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology Hospital de Baza  Granada Spain"},{"name":"Translational Research Institute Hamad Medical Corporation  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Abdulla","sequence":"additional","affiliation":[{"name":"Translational Research Institute Hamad Medical Corporation  Doha Qatar"},{"name":"Department of Dermatology and Venereology Hamad Medical Corporation  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Al\u2010Obaidli","sequence":"additional","affiliation":[{"name":"Translational Research Institute Hamad Medical Corporation  Doha Qatar"},{"name":"Department of Dermatology and Venereology Hamad Medical Corporation  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Ali\u2010Alam","sequence":"additional","affiliation":[{"name":"Translational Research Institute Hamad Medical Corporation  Doha Qatar"},{"name":"Department of Dermatology and Venereology Hamad Medical Corporation  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Steinhoff","sequence":"additional","affiliation":[{"name":"Translational Research Institute Hamad Medical Corporation  Doha Qatar"},{"name":"Department of Dermatology and Venereology Hamad Medical Corporation  Doha Qatar"},{"name":"Weill Cornell Medicine\u2010Qatar College of Medicine  Doha Qatar"},{"name":"Qatar University Medical School  Doha Qatar"},{"name":"Department of Dermatology Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.05.027"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2020-101502"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142205"},{"key":"e_1_2_9_5_1","unstructured":"http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959. Accessed March 2022."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.032"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776"},{"key":"e_1_2_9_8_1","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03800979?term=tofacitinib&cond=alopecia+areata&draw=2&rank=1. Accessed March 2022."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.260"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_21_18"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13598"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","DOI":"10.1111\/jocd.13966","article-title":"Experience with oral tofacitinib in severe alopecia areata with different clinical responses","volume":"20","author":"Dincer Rota D","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.007"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.006"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14422"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15937"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15489"},{"issue":"1","key":"e_1_2_9_19_1","first-page":"41","article-title":"Comparison of the treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: a retrospective study","volume":"99","author":"Shin JW","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.080"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000494613"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15383"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000510673"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32987-8"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120152"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121131"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.15871","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dth.15871","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.15871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:37:48Z","timestamp":1788154668000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.15871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/dth.15871"],"URL":"https:\/\/doi.org\/10.1111\/dth.15871","archive":["Portico"],"relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"2022-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15871"}}